Nasal spray of party drug shows promise as fast-acting antidepressant, researchers say

The latest clinical trial of esketamine, the nasal-spray form of the club drug ketamine, is boosting confidence among some psychiatrists that it could be a major advance in the treatment of suicidal depression. In a study published this week in the American Journal of Psychiatry, researchers report that an esketamine trial resulted in a “rapid improvement in depressive symptoms” […]Related:E. coli outbreak spreads as source of tainted lettuce remains a mysteryFirst marijuana-derived drug poised for FDA approval after winning support from advisersNew CDC chief stepped down from four groups to comply with ethics rules
Source: Washington Post: To Your Health - Category: Consumer Health News Source Type: news